TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01134432
Drug: prednisolone + mabthera
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.~Mabthera: 375 mg/m2 once a week for four weeks
Study: NCT01134432
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months
Study: NCT02658799
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
Study: NCT04010552
Drug: NALRINOX combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: NALRINOX: combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin
Study: NCT01645787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover study involving one trial with sugar pill (placebo)
Study: NCT03790371
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal placebo tablet prior IUD insertion
Study: NCT00435760
Drug: Placebo LAS34273
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 puff, 1 dat treatment
Study: NCT02463357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03742791
Drug: TS-134
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg to 80 mg oral solution
Study: NCT03742791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo oral solution
Study: NCT02620579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
Study: NCT03071549
Drug: Trichloroacetic acid peel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
Study: NCT01980706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill containing no pharmacologically active substance.
Study: NCT02125877
Drug: Defearisox film-coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
Study: NCT01288898
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01288898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02693860
Drug: huJ591
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute.
Study: NCT00786136
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin
Study: NCT03892330
Drug: Oxytetracycline/ Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Study: NCT03892330
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Study: NCT03892330
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Study: NCT01522612
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
Study: NCT00489827
Drug: Intravenous infusion of saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
Study: NCT04539652
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group are treated with TenofoBell®
Study: NCT00930163
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous repeating dose
Study: NCT00364000
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate in 240 chronic HD patients
Study: NCT01827865
Drug: Etodolac Extended Release Tablets USP 600mg
Normalized name: etodolac Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac Extended Release Tablets USP 600mg once a day
Study: NCT01827865
Drug: Etodolac Extended Release Tablets 600mg
Normalized name: etodolac Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac Extended Release Tablets 600mg once a day
Study: NCT02448368
Drug: RDEA3170, 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Study: NCT02448368
Drug: RDEA3170, 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Study: NCT01958073
Drug: Conjugated Estrogen Vaginal Cream
Normalized name: estrogens, conjugated (USP) Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01958073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03245827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule 25mg twice a week
Study: NCT00898287
Drug: P276-00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
Study: NCT01959295
Drug: ASP2151 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT01953536
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
Study: NCT02297399
Drug: PEG-ascorbate 2L
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 2 sachets (labelled A and B) of the investigational product and take their contents diluted in 1 liter of water. Two other sachets, also labelled A and B, will be taken diluted in 1 liter of water 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken.
Study: NCT00213252
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six daily doses of oral prednisolone
Study: NCT00103805
Drug: levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02537314
Drug: benzocaine
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
Study: NCT02512068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablets
Study: NCT01005537
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00003392
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 gm/m2 IV, day 1
Study: NCT03168256
Drug: CF101 3mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 tablets, 3mg BID for 16 weeks
Study: NCT03168256
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, BID for 16 weeks
Study: NCT00564954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally once a day for 7 days
Study: NCT01514188
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
Study: NCT02493426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00750581
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
Study: NCT01755494
Drug: Mertformin XR 2 x 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XR oral tablet 2 x 500 mg, single dose
Study: NCT01755494
Drug: Komboglyze XR 5/500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
Study: NCT01755494
Drug: Komboglyze XR 5/1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
Study: NCT01860625
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01392963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 29-40 U 0.9% NaCl injection
Study: NCT01689779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator drug
Study: NCT02026687
Drug: Epidural
Normalized name: Epidural 17g 3.5"
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02145091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral placebo (lactose pill).
Study: NCT03536741
Drug: General Intravenous Anesthetic
Normalized name: General intravenous anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Intravenous Anesthetic
Study: NCT02755649
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01049178
Drug: Oral Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Level 1: 1 capsules (1 cap at 140mg/cap) given three times per day for a total daily dose of 420 mg 28-days post Dose Level 1 Dose Level 2: 3 capsules (3 caps at 140mg/cap = 420 mg) given three times per day for a total daily dose of 1260 mg Day 56 (28-days post Dose Level 2) Dose Level 3: 5 capsules (5 caps at 140mg/cap = 700 mg) given three times per day for a total daily dose of 2100 mg Day 84 (28-days post Dose Level 3) We will evaluate change from baseline at each dose to determine the minimum effective dose.
Study: NCT01049178
Drug: Oral Silymarin, maintenance dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: The maintenance Silymarin dose will be selected based on the dose escalation study and will be dosed PO three times daily as recommended. Silymarin will be provided as a capsule S. marianum (70-80% silymarin), along with an identical appearance placebo capsule created by our investigational pharmacyAt each visit a questionnaire regarding daily symptoms and disease control, the asthma control test (ACT) will be completed, eNO measured, urine collected, spirometry (lung function) measured, venipuncture performed for blood collection (20 mL), as well as assessment of acceptability, toxicity, and masking.
Study: NCT01049178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03428711
Drug: Mesoglycan Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drug: mesoglycan, already used in the treatment of chronic venous ulcers, is a complex mucopolysaccharide, composed of a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~Used in oral formulation, hard capsules, 50 mg, twice-a-day, for 12 months. Reference therapy: placebo, organoleptically indistinguishable from the experimental drug, twice-a-day, for 12 months.
Study: NCT03428711
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indistinguible placebo tablet
Study: NCT03420911
Drug: dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03251170
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive :2.5 mcg/Kg fentanyl for induction of anesthesia
Study: NCT01499368
Drug: Lafutidine
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafutidine 20mg/day
Study: NCT01068262
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo tablet administered once weekly for 4 consecutive weeks
Study: NCT00576108
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel
Study: NCT04414618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
Study: NCT02590965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
Study: NCT04221230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00181558
Drug: Zoledronic Acid (Zometa)
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00641225
Drug: SBI-087
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
Study: NCT01399658
Drug: 3'-Deoxy-3'-18f-Fluorothymidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessing tumor proliferation in Gynecologic cancer
Study: NCT02279108
Drug: isotope
Normalized name: Radioisotope
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection, 20 MBq techntium99, intradermal use
Study: NCT04230902
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-articular knee injection of corticosteroid
Study: NCT01474200
Drug: IV Loop Diuretics (LD)
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial.
Study: NCT01625988
Drug: LY2951742
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01625988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00294580
Drug: Maloprim
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00824343
Drug: P276-00
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
Study: NCT01495702
Drug: NNRTI
Normalized name: Non-nucleoside reverse transcriptase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.
Study: NCT01493921
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient wil be instructed to self-apply approximately 0.3\~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
Study: NCT01375179
Drug: KRP203
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01375179
Drug: Placebo matching KRP203
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00599053
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/kg IV per dose given for 10 days
Study: NCT04612062
Drug: CEE321
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE321 administered to all subjects
Study: NCT01207895
Drug: [18F]-fluorodeoxythymidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]-fluorodeoxythymidine is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
Study: NCT02370524
Drug: [18F]T807
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
Study: NCT02661217
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 film-coated tables were supplied to the investigators. Tablets were taken with a glass of water, and were administered with or without food.~The target dose of LCZ696 was 200 mg twice daily. Starting dose of LCZ696 was either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient.
Study: NCT03168334
Drug: IDP-123 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.045% Lotion
Study: NCT01644617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rapidly dissolving tablets administered sublingually once daily
Study: NCT01644617
Drug: MK-8237 6 DU
Normalized name: vitamin MK 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily
Study: NCT01726920
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets containing naproxen 500 mg
Study: NCT01644617
Drug: MK-8237 12 DU
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
Study: NCT00377832
Drug: Acetaminophen 975 mg
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 975 mg by mouth once only
Study: NCT00958893
Drug: 25 mg Proellex
Normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 25 mg capsules
Study: NCT00475462
Drug: conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01907594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
Study: NCT00817518
Drug: RO4987655
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
Study: NCT02539082
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, normal saline, injection in the defect area
Study: NCT03930212
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: received placebo suppositories rectally once daily.
Study: NCT00271401
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00271401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02632708
Drug: AG-120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04671316
Drug: DA-5209 60mg Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration of 1 tablet of DA-5209 60mg Tab with 150mL water
Study: NCT04671316
Drug: DA-5209 60mg Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration of 1 tablet of DA-5209 60mg Tab without water
Study: NCT00425763
Drug: AQAS
Normalized name: Acetylsalicylic acid
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AQAS dosed by body weight, on days 0, 1, 2
Study: NCT02929888
Drug: Lysine Acetilsalicilate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01912378
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00369941
Drug: MK-0518
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks
Study: NCT00369941
Drug: Comparator: Truvada
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)